Analysis of over 11,000 participants in the SUSTAIN and PIONEER trials revealed that gastrointestinal disorders were the predominant adverse effects, occurring in approximately 39-42% of semaglutide users compared to 22-25% of those receiving comparators
These were not direct head-to-head trials, so the comparison should be interpreted carefully
More than two dozen studies presented over the past few days at the American Society of Clinical Oncology meeting in Chicago found that patients taking the drugs showed lower risks of developing cancer and disease progression, better survival, and improved responses to some treatments, compared with people who were not taking the GLP-1s
These emerging side effects demonstrate a pattern of inadequate safety monitoring and delayed warnings with some conditions like ileus carrying life-threatening consequences and others like deep vein thrombosis potentially causing fatal pulmonary embolisms
Semaglutide and tirzepatide promote hormonal balance, which makes them effective at helping your body break down stored fat for energy